Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabienne Brilot

Showing results (91-100 of 128) with videos related to

Pageof 13
Sort By:
Neurology(R) Neuroimmunology & Neuroinflammation|October 24, 2014
Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeletonRussell C Dale, Esther M Tantsis, Vera Merheb, et al.
Clinical & Translational Immunology|January 11, 2021
Pro-inflammatory dopamine-2 receptor-specific T cells in paediatric movement and psychiatric disordersDeepti Pilli, Alicia Zou, Ruebena Dawes, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 28, 2025
MOG antibody non-P42 epitope is associated with a higher risk of relapse in paediatric MOGADAseel El Hajj, Anne Ruiz, Antoine Gavoille, et al.
Clinical & Translational Immunology|December 22, 2025
Polyfunctional T peripheral helper cells are associated with the magnitude and durability of antibody responses after COVID-19Katie Tungatt, Gabriela Martins Costa Gomes, Nicole L Fewings, et al.
American Journal of Hematology|May 24, 2022
Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responsesBrendan Beaton, Sarah C Sasson, Katherine Rankin, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 4, 2014
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritisSudarshini Ramanathan, Stephen W Reddel, Andrew Henderson, et al.
Annals of Neurology|August 9, 2021
Leucine-Rich Glioma-Inactivated 1 versus Contactin-Associated Protein-like 2 Antibody Neuropathic Pain: Clinical and Biological ComparisonsSudarshini Ramanathan, Mandy Tseng, Alexander J Davies, et al.
The Journal of Applied Laboratory Medicine|October 31, 2021
Validation of a Flow Cytometry Live Cell-Based Assay to Detect Myelin Oligodendrocyte Glycoprotein Antibodies for Clinical DiagnosticsJoseph A Lopez, Samuel D Houston, Fiona Tea, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 14, 2024
Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapseBenjamin P Trewin, Russell C Dale, Jessica Qiu, et al.
BMJ Open|April 24, 2026
Comparison of immunity-boosting regimens for COVID-19 upon initiation of immunosuppressive therapy (CIRCUIT): study protocol for a randomised, controlled clinical trialDianne L Carey, Golo Ahlenstiel, Fabienne Brilot, et al.
Pageof 13

Showing results (91-100 of 128) with videos related to

Sort By:
Pageof 13
Neurology(R) Neuroimmunology & Neuroinflammation|October 24, 2014
Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeletonRussell C Dale, Esther M Tantsis, Vera Merheb, et al.
Clinical & Translational Immunology|January 11, 2021
Pro-inflammatory dopamine-2 receptor-specific T cells in paediatric movement and psychiatric disordersDeepti Pilli, Alicia Zou, Ruebena Dawes, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 28, 2025
MOG antibody non-P42 epitope is associated with a higher risk of relapse in paediatric MOGADAseel El Hajj, Anne Ruiz, Antoine Gavoille, et al.
Clinical & Translational Immunology|December 22, 2025
Polyfunctional T peripheral helper cells are associated with the magnitude and durability of antibody responses after COVID-19Katie Tungatt, Gabriela Martins Costa Gomes, Nicole L Fewings, et al.
American Journal of Hematology|May 24, 2022
Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responsesBrendan Beaton, Sarah C Sasson, Katherine Rankin, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 4, 2014
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritisSudarshini Ramanathan, Stephen W Reddel, Andrew Henderson, et al.
Annals of Neurology|August 9, 2021
Leucine-Rich Glioma-Inactivated 1 versus Contactin-Associated Protein-like 2 Antibody Neuropathic Pain: Clinical and Biological ComparisonsSudarshini Ramanathan, Mandy Tseng, Alexander J Davies, et al.
The Journal of Applied Laboratory Medicine|October 31, 2021
Validation of a Flow Cytometry Live Cell-Based Assay to Detect Myelin Oligodendrocyte Glycoprotein Antibodies for Clinical DiagnosticsJoseph A Lopez, Samuel D Houston, Fiona Tea, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 14, 2024
Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapseBenjamin P Trewin, Russell C Dale, Jessica Qiu, et al.
BMJ Open|April 24, 2026
Comparison of immunity-boosting regimens for COVID-19 upon initiation of immunosuppressive therapy (CIRCUIT): study protocol for a randomised, controlled clinical trialDianne L Carey, Golo Ahlenstiel, Fabienne Brilot, et al.
Pageof 13